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H I G H L I G H T S
• Ayahuasca (Aya) did not exert effects on the spontaneous locomotor activity of mice.
• Aya prevented the development of ethanol(Eth)-induced behavioral sensitization (BS).
• At high doses, Aya also inhibited acute Eth-induced hyperlocomotion.
• An 8-day treatment with Aya in the open-ﬁeld did not induce BS to this drug.
• Counter-sensitization with Aya blocked the reinstatement of Eth-induced BS.⁎ Correspondence to: L.F. Berro, Departmento de Psicob
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Background: Hallucinogenic drugs were used to treat alcoholic patients in the past, and recent developments in
the study of hallucinogens led to a renewal of interest regarding the application of these drugs in the treatment
of addiction. In this scenario, accumulating evidence suggests that the hallucinogenic brew ayahuasca (Aya)may
have therapeutic effects on substance abuse problems.
Methods: We investigated the effects of Aya on spontaneous locomotor activity and ethanol(Eth)-induced
hyperlocomotion and subsequent locomotor sensitization by a two-injection protocol. Additionally, we tested
the effect of Aya on an 8-day counter-sensitization protocol tomodify sensitized responses induced by a repeated
treatment with Eth (1.8 g/kg) for 8 alternate days.
Results: Aya showed high sensitivity in preventing the development of Eth-induced behavioral sensitization, at-
tenuating it at all doses (30, 100, 200, 300 or 500 mg/kg) without modifying spontaneous locomotor activity. At
the highest doses (300 and 500 mg/kg), Aya also showed selectivity to both acute and sensitized Eth responses.
Finally, a counter-sensitization strategy with 100 or 300 mg/kg of Aya for 8 consecutive days after the establish-
ment of Eth-induced behavioral sensitization was effective in blocking its subsequent expression on an Eth chal-
lenge.
Conclusions:Wedemonstrated that Aya not only inhibits early behaviors associatedwith the initiation and devel-
opment of Eth addiction, but also showed effectiveness in reversing long-term drug effects expression, inhibiting
the reinstatement of Eth-induced behavioral sensitization when administered in the Eth-associated
environment.© 2015 Elsevier Inc. All rights reserved.iologia, Universidade Federal de São Paulo, R. Napoleão de Barros, 925, 1° andar, 04024002 São Paulo, SP, Brazil.
Ciências da Saúde, Universidade Estadual de Santa Cruz, Rod. Ilhéus/Itabuna, Km 16, 45662-0 Ilhéus, BA, Brazil.
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Alcohol (ethanol) abuse is amajor contributor tomore than 60 types
of diseases and injuries and accounts for approximately 2.5 million
deaths each year [38]. Ethanol addiction is a chronic and often progres-
sive and fatal diseasewith genetic, psychosocial, and environmental fac-
tors inﬂuencing its development and manifestations [28]. Currently
available psychological and pharmacological treatments are only par-
tially effective [3] and further research on new intervention approaches
remain necessary.
Hallucinogenic drugs were used to treat alcoholic patients
during the decades of 1960 and early seventies. These studies came
prematurely to a halt due to the classiﬁcation of hallucinogens into
Schedule I class, i.e., drugs with high abuse potential, no accepted
therapeutic use and lack of accepted level of safety for use under
medical supervision. After four decades banned fromhuman psychiatric
research, hallucinogen research has resumed by using psilocybin,
a serotonergic hallucinogen, to treat alcoholism and nicotine depen-
dence [4].
Accumulating evidence from observational epidemiological studies
suggests that the hallucinogenic brew ayahuasca may have therapeutic
effects on substance related problems. This brew is produced from the
decoction of N,N-dimethyltryptamine (DMT) and harmala alkaloid-
containing plants, such as harmine, tetrahydroharmine (THH) and
harmaline [26], and is used in syncretic religions in major cities of
Brazil and parts of Europe, Japan, Canada, and the USA [40]. Case–con-
trol, longitudinal and cross-sectional studies showed that ritual and re-
ligious ayahuasca users present fewer alcohol-related problems than
control groups and that drug use diminished after joining ayahuasca
churches [13,20,22,39]. It is an open question whether ayahuasca has
anti-addictive properties per se or if the social factors (e.g. religious so-
cial reinforcement) play a major role in these results [2]. By ruling out
the ceremonial religious aspects of the aforementioned studies, phar-
macological studies using rodent models can contribute to elucidate
the role of the brew per se into the neurobiological mechanisms of aya-
huasca on alcohol-related behavior.
In the current paper we used the behavioral sensitization model to
investigate the effects of ayahuasca on alcohol-related behavior in
mice. Alcohol increases dopamine levels in the nucleus accumbens,
which elicits locomotor stimulation in rodents, and repetitive adminis-
tration intensiﬁes this response [37]. This phenomenon called behavior-
al sensitization is thought to be an underlying adaptation responsible
for addiction to drugs of abuse and to share neuronal mechanisms
with craving [33]. Behavioral sensitization depends on the temporal
pattern of drug exposure. Repeated intermittent treatment regimens
are usuallymore effective to induce sensitization than continuous expo-
sure to high or escalating drug doses [32,37,44]. However, single dose
drug abuse exposure has also been reported to induce long-termbehav-
ioral sensitization [42,43].
Additionally, an important aspect concerning both drug craving
in humans and behavioral sensitization in rodents is the potentiating
effect of environmental cues previously paired with drug effects
on their development [7,9,15,29]. Therefore, recent efforts to
develop effective treatments for addiction have focused on manipula-
tions of learning and memory processes involved in encoding drug-
cue associations. In this scenario, it has been suggested that re-
consolidation and/or counter-sensitization procedures permit the ther-
apeutic drug treatment to become linked to the contextual stimuli and
in effect form a new and different drug association with the contextual
cues.
This paper reports two experiments designed to evaluate the effects
of ayahuasca on ethanol-related behaviors. In the ﬁrst experiment, we
evaluated the effects of ayahuasca on mice spontaneous locomotion in
the open-ﬁeld apparatus, hyperlocomotion induced by ethanol and
ethanol-induced behavioral sensitization in a single injection protocol.
The second experiment was designed to test the effect of ayahuascaon a counter-sensitization protocol to modify sensitized responses in-
duced by a repeated treatment with ethanol.2. Material and methods
2.1. Animals
Male 3-month-old Swiss EPM-M2 mice (30–35 g) were obtained
from the Centre for Development of Experimental Models in Medicine
and Biology of Braz Cubas University. Animals were housed in groups
of 12 in polypropylene cages (32 cm × 42 cm × 18 cm) under con-
trolled temperature (22–23 °C) and lighting (12/12 h light/dark; lights
on at 6 h 45 a.m.) conditions. Food and water were available ad libitum
throughout the experiments. The experiments were performed in ac-
cordance with the National Institute of Health Guide for the care and
use of laboratory animals (NIH Publications No. 80–23, revised 1996),
and animals were maintained in accordance with the Brazilian Law for
Procedures for Animal Scientiﬁc Use (#11794/2008). The experimental
procedures were approved by the Institutional Ethical Committee of
Braz Cubas University under the protocol #176/2008.2.2. Drugs
One liter batch of ayahuascawas obtained by amember of the Santo
Daime church. The liquid was lyophilized and rendered 88 g of freeze
dried material. The ratio of dry tea/volume of liquid tea was calculated
to establish the doses to be administered in the experiments.
Ethanol (Merck®) and ayahuasca were diluted in saline 0.9% solu-
tion. All solutions were given intraperitoneally (i.p.) at a volume of
10 ml/kg of body weight. Ethanol was administered at the dose of
1.8 mg/kg. The dose of ethanol was chosen based on previous studies
showing that if is effective in inducing both acute and sensitized loco-
motor responses in mice [10,17,24].2.3. Ayahuasca compounds analysis
In order to quantify the amount of the main compounds of ayahua-
sca (DMT, tetrahydroharmine, harmine and harmaline) in our prepara-
tion, the sample of ayahuasca was analyzed by liquid chromatography-
tandem mass spectrometry (LC-MS/MS) conducted on a high perfor-
mance liquid chromatography equipment Prominence system
(Shimadzu, Kyoto, Japan). The analysis was conducted by the Criminal-
istics Institute of São Paulo.
Harmine hydrochloride and harmaline hydrochloride were pur-
chased from Sigma®. The synthesis of tetrahydroharmine was
performed according to previously published procedure [46] and
DMT was synthesized according to a modiﬁed procedure based on
the selective dimethylation method [47,48]. The stock solutions
(1.0 mg/ml) of DMT, harmine, harmaline and tetrahydroharmine
were prepared inmethanol and stored at−20 °C until the performance
of the LC-MS/MS.2.4. Open-ﬁeld evaluation
Locomotor activity was measured in an open ﬁeld apparatus previ-
ously described by [9]. The apparatus is a circular wooden arena
(40 cm in diameter and 50 cm high)with an open top and a ﬂoor divid-
ed into 19 squares. Hand-operated counterswere used to score the loco-
motion frequency (total number of any square entered) during 10-min
sessions by an observer, whowas blind to the treatment allocation. Ten-
minute sessions were proposed because it has been shown that even
shorter periods are effective in reliably evaluating the effects of drugs
acting on dopaminergic systems [8,16].
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2.5.1. Experiment 1. Effects of ayahuasca on spontaneous locomotor activi-
ty, acute ethanol-induced hyperlocomotion and ethanol-induced behavior-
al sensitization
Eighty mice were given a 10-min habituation period in the open-
ﬁeld on 2 consecutive days after a saline i.p. injection. Basal locomotor
activity was measured on day 2. Six groups of animals were formed
(n = 10 or 30), which were statistically equivalent with respect to the
basal levels of locomotor activity. Previous habituation sessions are im-
portant to ensure the accuracy of the data due to the effect that environ-
mental novelty exerts on spontaneous [21], ethanol- [17] and
hallucinogenic drugs-induced locomotor activity [21].
On the third day, animals were i.p. acutely treated with saline (Sal,
n = 30) or ayahuasca at the doses of 30, 100, 200, 300 or 500 mg/kg
(Aya, n = 10 for each group) followed by initial exposure to the open-
ﬁeld environment 30 min after treatment to quantify their locomotor
activities. During the interval between the treatment and the open-
ﬁeld exposure, animals were returned to their home-cages (animals
under the same treatment housed together). A 30-min interval between
the injection of ayahuasca and the open-ﬁeld exposure was determined
based on previous studies showing that hallucinogenic drugs might
show a biphasic locomotor proﬁle, with drug-induced hyperlocomotion
only being observed after longer post-treatment periods [21,27]. The
following groups were compared in the ﬁrst open-ﬁeld exposure: Sal,
Aya30, Aya100, Aya200, Aya300 and Aya500. Immediately after the
ﬁrst behavioral evaluation, or 40 min after the saline/ayahuasca injec-
tion, 20 animals from the Sal group received a saline i.p. injection, and
the remaining 10 mice were treated with 1.8 g/kg i.p. ethanol (Eth).
All animals pretreatedwith ayahuasca also received1.8 g/kg i.p. ethanol.
After the second treatment, animals were placed in a clean cage until
the subsequent exposure to the open-ﬁeld apparatus. Five minutes
after administration of either saline or ethanol, animals were returned
to the open-ﬁeld and for locomotion quantiﬁcation. Thus, the following
groups were formed: Sal–Sal, Sal–Eth, Aya30–Eth, Aya100–Eth,
Aya200–Eth, Aya300–Eth and Aya500–Eth.
Seven days later, 10 out of 20 animals that were treated twice with
saline on the previous week (Sal–Sal group) received a saline i.p. injec-
tion again (forming the Sal–Sal–Sal group) and the remaining 10 mice
were treated with 1.8 g/kg i.p. ethanol for the ﬁrst time (forming the
Sal–Sal–Eth group). Ethanol (1.8 g/kg) was also administered to all the
other animals for the second time, forming the Sal–Eth–Eth, Aya30–
Eth–Eth, Aya100–Eth–Eth, Aya200–Eth–Eth, Aya300–Eth–Eth and
Aya500–Eth–Eth groups. After treatment, animals were placed in a
clean cage until their behavioral evaluations. Five minutes after the in-
jections,micewere placed in the open-ﬁeld for locomotor activity quan-
tiﬁcation. The experimental design of Experiment 1 is summarized in
Fig. 1.
2.5.2. Experiment 2. Effects of ayahuasca on a counter-sensitization proto-
col to modify sensitized responses induced by a repeated treatment with
ethanol
Sixty-six mice were given a 10-min habituation period in the open-
ﬁeld on 2 consecutive days after a saline i.p. injection. Basal locomotor
activity was measured on day 2. Six groups of animals were formedFig. 1. Design of experiment 1. OFQ: Open-ﬁeld quantiﬁcation; Sal: saline i.p. injection; Aya:
injection.(n = 11 for each group), which were statistically equivalent with re-
spect to the basal levels of locomotor activity. Twenty-four hours after
the second habituation day, the behavioral sensitization procedure
began. Three groups of animals received an i.p. injection of saline (Sal
groups) and the other 3 groups were treated with 1.8 g/kg ethanol
(Eth groups) 5 min prior to being placed in the open-ﬁeld apparatus
every other day for 15 days from the 3th to 17th days (ethanol-induced
behavioral sensitization, sensitization phase). After treatments, animals
were placed in a clean cage until their behavioral evaluations. During
the alternate non-sensitization days, mice were left undisturbed in
their home-cages. On days 3 and 17 animals were observed for the
quantiﬁcation of their locomotion frequency.
Forty-eight hours after the last injection of the sensitization phase
(19th day), the counter-sensitization protocol began. For 8 consecutive
days (19th to 26th days) 11 animals from the Sal group received daily
saline i.p. injections (Sal–Sal group) and the remaining mice received
daily i.p. injections of ayahuasca (Aya) at the doses of 100 (Sal–
Aya100, n = 11) or 300 (Sal–Aya300, n = 11) mg/kg. Those doses
were chosen because in the ﬁrst experiment 100 mg/kg of ayahuasca
was the highest dose that speciﬁcally prevented ethanol-induced be-
havioral sensitization and 300 mg/kg was the lower dose that inhibited
both ethanol-induced hyperlocomotion and behavioral sensitization.
The ethanol-sensitized groups underwent the same procedure. Eleven
animals from the Eth group received daily saline i.p. injections (Eth–
Sal group) and the remaining mice received daily i.p. injections of aya-
huasca at the doses of 100 (Eth–Aya100, n = 11) or 300 (Eth–Aya300,
n = 11) mg/kg. Therefore, the following groups were formed: Sal–Sal,
Sal–Aya100, Sal–Aya300, Eth–Sal, Eth–Aya100 and Eth–Aya300. During
the interval between the treatment and the open-ﬁeld exposure, ani-
malswere returned to their home-cages (animals under the same treat-
ment housed together). Thirty minutes after each administration of
saline or ayahuasca, animals were individually exposed to the open-
ﬁeld arena for 10-min sessions (counter-sensitization phase).
Four days after the last counter-sensitization day (30th day), all an-
imals received an i.p. saline injection andwere placed, 5min later, in the
open-ﬁeld apparatus for quantiﬁcation of their locomotion frequency.
Two days after the Saline challenge, animals were tested for drug-
induced reinstatement of ethanol-induced behavioral sensitization
(day 32). All animals received an i.p. injection of 1.8 g/kg ethanol and
were placed, 5 min later, in the open-ﬁeld apparatus for quantiﬁcation
of their locomotion frequency. In both saline and ethanol challenge ses-
sions, animals were placed in a clean cage during the interval between
the treatment and the behavioral evaluation. The experimental design
of Experiment 2 is summarized in Fig. 2.2.6. Statistical analysis
Before conducting the statistical analysis, all variables were checked
for normality (Shapiro–Wilk test) and homogeneity (Levene's test),
which validated the use of the parametric tests. Data were analyzed
by 1 or 2-way ANOVA, and multiple comparisons were performed
using the Tukey's post hoc test when necessary or the paired Student
t-test. A p value less than 0.05 was considered as a statistically signiﬁ-
cant difference.ayahuasca (30, 100, 200, 300 or 500 mg/kg) i.p. injection; and Eth: ethanol 1.8 g/kg i.p.
Fig. 2. Design of experiment 2. OFQ: Open-ﬁeld quantiﬁcation; Sal: saline i.p. injection; Aya: ayahuasca (100 or 300 mg/kg) i.p. injection; and Eth: ethanol 1.8 g/kg i.p. injection.
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3.1. Ayahuasca compound analysis
LC-MS/MS analysis indicated the following active constituents in our
sample of ayahuasca:
– DMT: 0.4 mg/100 mg (35 mg/ml of initial batch)
– Tetrahydroharmine: 3.07 mg/100 mg (2.70 mg/ml of initial batch)
– Harmine: 3.85 mg/100 mg (3.39 mg/ml of initial batch)
– Harmaline: 0.17 mg/100 mg (0.15 mg/ml of initial batch).
3.2. Experiment 1. Effects of ayahuasca on spontaneous locomotor activity,
acute ethanol-induced hyperlocomotion and ethanol-induced behavioral
sensitization
Analysis of the secondhabituation sessionusing1-wayANOVArevealed
no signiﬁcant difference between groups [F(5,74) = 0.09; p = 0.99]
(datanot shown). In theﬁrst behavioral evaluationafter salineor ayahuasca
administration (spontaneous locomotor activity), ANOVA did not reveal
signiﬁcant differences between groups [F(5,74)=0.41; p=0.83], demon-
strating that, at all doses, ayahuasca did notmodify spontaneous locomotor
activity per se (Fig. 3a).
In the evaluation of acute ethanol-induced hyperlocomotion after
ayahuasca treatment, statistically signiﬁcant differences were observed
between groups [F(6,73) = 11.74; p b 0.0001]. An acute ethanol effect
was observed based on the signiﬁcantly higher locomotion frequency
of the Sal–Eth group compared to the Sal–Sal group (Tukey's test,
p b 0.001). Ayahuasca at the doses of 30, 100 and 200 mg/kg did
not affect acute ethanol-induced hyperlocomotion. However, at
the doses of 300 and 500 mg/kg, ayahuasca prevented the acute
stimulating effect of ethanol (Tukey's test, p b 0.05) (Fig. 3b).
Mice were previously exposed/habituated to the open-ﬁeld during
the spontaneous locomotion evaluation for the subsequent within-day
session on the ﬁrst ethanol challenge and were re-exposed to the
open-ﬁeld on the test session only 7 days after the ﬁrst ethanol injec-
tion. These different conditions could affect the locomotor activity of
mice per se. Thus, to avoid an effect of these habituation factor
between-sessions, the locomotor frequencies of mice were evaluated
within-session, compared to the respective control groups. After one
week, ethanol-induced locomotor sensitization was evaluated, and
statistically signiﬁcant differences were observed [F(7,72) = 7.87;
p b 0.0001]. As shown in Fig. 3c, an acute ethanol injection for the
ﬁrst time induced enhanced locomotion frequency (Sal–Sal–Eth N
Sal–Sal–Sal), which was potentiated in the Sal–Eth–Eth group
(Sal–Eth–Eth N Sal–Sal–Eth) (Tukey's test, p b 0.05), indicating
the development of behavioral sensitization. Treatment with ayahuasca
at all doses before theﬁrst ethanol administration prevented the develop-
ment of ethanol-induced sensitization, as shown by a signiﬁcant decrease
in the locomotor activity of these groups compared to the Sal–Eth–EthFig. 3. Locomotor activity quantiﬁcation in the open-ﬁeld apparatus demonstrating the behavio
saline on (a) spontaneous locomotor activity and its subsequent effects on (b) acute hyperlocom
after a 7-day interval. Data are reported asmean ± S.E.M.★ p b 0.05 comparedwith Sal–Sal (b)
compared with Sal–Sal–Eth (c). One- or two-way analysis of variance (ANOVA) followed by Tugroup (Tukey's test, p b 0.05). These data together indicate that ayahuasca
prevented the development of single dose ethanol-induced behavioral
sensitization even at doses that did not inhibit acute ethanol-induced
hyperlocomotion.3.3. Experiment 2. Effects of ayahuasca on a counter-sensitization protocol
to modify sensitized responses induced by a repeated treatment with
ethanol
Analysis of the second habituation session using Student t-test re-
vealed no signiﬁcant difference between groups [t(64) = 0.0085;
p = 0.99] (data not shown).
For the ethanol-induced behavioral sensitization analysis (sensitiza-
tion phase), 2-way ANOVA with repeated measures showed a signiﬁ-
cant interaction effect between time (Day 3 vs Day 17) and treatment
(ethanol vs saline) [F(5,60) = 2.70; p b 0.05]. As illustrated in Fig. 4a,
Tukey's post hoc test showed that the acute ethanol injection (ﬁrst day
of sensitization phase) induced a signiﬁcant increase in the locomotor
activity of mice (Eth groups N Sal groups), thereby revealing the
locomotor-stimulating effect of ethanol. In addition, paired t-test
demonstrated that repeated treatmentwith ethanol increased the loco-
motor activity of the animals, as demonstrated by an increased locomo-
tion of ethanol-treated groups on Day 17 compared with Day 3, thereby
revealing the development of behavioral sensitization.
For the analysis of the counter-sensitization phase with ayahuasca, 2-
way ANOVA with repeated measures revealed no signiﬁcant effect of pre-
treatment (ethanol vs saline) [F(1,60) = 0.370; p = 0.54], counter-
sensitization treatment (ayahuasca vs saline) [F(1,60) = 0.282; p = 0.75]
and time (Day 19 vs Day 26) [F(1,60) = 1.57; p= 0.21] or interaction be-
tween these factors [F(1,60)=0.66; p=0.93]. This result suggests that an-
imals pre-treated with ethanol did not differ from the Sal group, and that,
again, ayahuasca per se did not modify locomotor activity, even after a
treatment for 8 consecutive days (Fig. 4b).
Four days after the last counter-sensitization phase (day 30), 2-way
ANOVA revealed no signiﬁcant effect of pre-treatment (ethanol vs sa-
line) [F(1,60) = 2.43; p = 0.12] and counter-sensitization treatment
(ayahuasca vs saline) [F(1,60)=0.12; p=0.88] or interaction between
these factors [F(1,60) = 0.81; p = 0.45] during the saline challenge
(Fig. 4c).
However, during the Ethanol challenge, 2-way ANOVA revealed a
signiﬁcant interaction effect between pre- (ethanol vs saline) and
counter-sensitization (ayahuasca vs saline) treatments [F(2,60) = 4.95;
p b 0.01]. As illustrated in Fig. 4c, paired t-test showed that an acute eth-
anol injection promoted an enhanced locomotion frequency in the group
that was experiencing ethanol for the ﬁrst time, as shown by a higher lo-
comotion frequency of Sal–Sal group on the ethanol challenge compared
to itself on the saline challenge. Of note, previous treatment with
ayahuasca for 8 consecutive days did not inhibit the acute ethanol-
induced hyperlocomotion phenomenon, because Sal–Aya100 and
Sal–Aya300 groups did not differ from Sal–Sal group on the ethanol
challenge day.ral effects of i.p. treatment with either ayahuasca (Aya, 30, 100, 200, 300 or 500 mg/kg) or
otion induced by ethanol (Eth, 1.8 g/kg) and (c) ethanol-induced behavioral sensitization
or Sal–Sal–Sal (c);♦ p b 0.05 comparedwith Sal–Eth (b) or Sal–Eth–Eth (c); and • p b 0.05
key's test.
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groupwas potentiated in Eth–Sal group (Tukey's test, p b 0.05), indicat-
ing the expression of behavioral sensitization reinstatementwith a new
ethanol challenge in the group previously and repeatedly sensitized with
ethanol that received saline during the counter-sensitization phase
even after 15 days of drug withdrawal. However, Tukey's test indicated
that the groups previously sensitized with ethanol and treated with 100
or 300 mg/kg of ayahuasca in the counter-sensitization phase (Eth–
Aya100 and Eth–Aya300 groups), showed a lower locomotor activity
compared to the group pretreated with ethanol in the sensitization
phase but treated with saline in the counter-sensitization phase (Eth–
Sal N Eth–Aya100 and Eth–Aya300). Moreover, the locomotor activity
of both groups pre-treated with ethanol in the sensitization phase and
treated with ayahuasca in the counter-sensitization phase (Eth–
Aya100 and Eth–Aya300 groups) did not differ from that showed by
the group pretreated with saline which received ethanol for the ﬁrst
time in the Ethanol challenge (Sal–Sal group). Taken together, these re-
sults indicate that the counter-sensitization with ayahuasca at both
doses was effective in blocking the expression of the reinstatement of
ethanol-induced behavioral sensitization.
4. Discussion
The most important ﬁndings of the present study were the follow-
ing: (1) ayahuasca showed high sensitivity in preventing the develop-
ment of ethanol-induced behavioral sensitization because it was
attenuated by all tested doses, even lower doses than those required
to reduce acute ethanol response, withoutmodifying spontaneous loco-
motor activity; (2) at the highest doses (300 and 500mg/kg), ayahuasca
showed selectivity to both acute and sensitized ethanol responses,
blocking these phenomena without affecting spontaneous locomotor
activity; (3) a prolonged 8-day treatmentwith 100 or 300mg/kg of aya-
huasca in the open-ﬁeld apparatus did not implicate in thedevelopment
of behavioral sensitization to this substance; and (4) counter-
sensitization with 100 or 300 mg/kg of ayahuasca in the open-ﬁeld for
8 consecutive days after the establishment of behavioral sensitization
to ethanol was effective in blocking the expression of the reinstatement
of ethanol-induced behavioral sensitization.
The presumed biochemical mechanism of action for ayahuasca
brews includes the presence of beta-carboline monoamine oxidase in-
hibitors (harmala alkaloids) coupled with dimethyltryptamine, a com-
pound that acts on speciﬁc serotonin receptors, particularly 5-HT2A
receptors [5]. Evidence of 5-HT receptor agonist activity has been re-
ported in a drug-discriminant animal model study [36]. However 5-
HT2 receptor antagonist activity of DMT reported in a previous in vitro
study [11] suggests that the purported agonist or antagonist properties
of this compound deserve further investigation. Regarding the inhibito-
ry effects of ayahuasca on ethanol-induced hyperlocomotion showed in
the present study (Fig. 3b), it has been demonstrated that treatment
with ritanserin, a 5HT2A/2C receptor antagonist, caused a dose-
dependent reduction of ethanol-induced auto-administration and loco-
motor activity [19]. In addition, a recent study from our group demon-
strated that pre-treatment with ziprasidone, an antipsychotic drug
with high afﬁnity for both dopamine D2 and 5-HT receptors that acts
as a potent 5-HT2A receptor antagonist [35], inhibited not only acute
cocaine-induced hyperlocomotion, but also cocaine-induced behavioral
sensitization [25].
Within this context, there is extensive experimental evidence dem-
onstrating that in addition to dopaminergic transmission, serotonergic
transmission is necessary for the development of ethanol-inducedFig. 4. Locomotor activity quantiﬁcation in the open-ﬁeld apparatus demonstrating acute hyp
sensitization (Day 15) after a 15-day intermittent treatment (8 ethanol injections) (a) and
or saline on the counter-sensitization phase for 8 consecutive days (Day 19 toDay 26) (b) andon
S.E.M. • p b 0.05 compared with itself on the ﬁrst ethanol treatment day (Day 1) (a);★ p b 0.05
with Eth–Sal (c); and ■ p b 0.05 compared with itself on the saline challenge. Two-way analysbehavioral sensitization. Treatment with the serotonergic antagonist
ondansetron blocks the development and expression of ethanol-
induced locomotor sensitization [41]. Indeed, simultaneous treatment
with a serotonin 5-HT2 receptor antagonist exerts the same effects,
preventing the induction and expression of ethanol-induced behavioral
sensitization [14]. Additionally, the administration of the 5-HT2C recep-
tor antagonist SB-242084 directly into the nucleus accumbens blocked
the expression of ethanol-induced behavioral sensitization in mice [1].
Taken together, these ﬁndings are in line with the high selectivity of
ayahuasca in inhibiting both ethanol-induced hyperlocomotion and be-
havioral sensitization (Fig. 3b and c).
Importantly, despite an altered state of consciousness linked to the
use of ayahuasca [31], the ritual use of this substance does not typically
produce health or psychosocial problems such as addiction [12,13]. In-
deed, a review of the literature on ayahuasca suggests that consumption
of traditional preparations in social settings carries a minimal risk of
abuse potential or dependence formation [18]. Within this context,
our results are among the ﬁrst to demonstrate that acute (Figs. 3a and
4b) or repeated (Fig. 4b) treatments with ayahuasca do not lead to en-
hanced locomotor activity in mice, a well-established parameter as an
animal model of addiction that shares neuronal mechanisms with crav-
ing in humans [33].
Rather, ceremonial ayahuasca drinking has been correlated with
lower amounts or severities of substancedependence. Importantly, clin-
ical studies carried with members from Brazilian ayahuasca churches
demonstrated that these ayahuasca users show less substance abuse
disorders despite prior histories of moderate to severe problems with
alcohol or other drugs and higher lifetime illicit drug use [13,20]. How-
ever, all these studies involve subjects who are regular and committed
members of religious communities, so it remained unclear whether
fewer reported substance use problems could be attributed to the aya-
huasca drinking rather than being a church member. By ruling out the
ceremonial religious aspects of the aforementioned studies, pharmaco-
logical studies using rodent models can contribute to elucidate the role
of the brew per se into the neurobiologicalmechanisms of ayahuasca on
alcohol-related behavior.
As far as we know, this is the ﬁrst study showing that a counter-
sensitization strategy with ayahuasca inhibits the expression of a pre-
established ethanol-induced behavioral sensitization (Fig. 4c). Usually,
as showed in the present study (Fig. 4b), ethanol-treated animals do
not express a conditioned locomotion in the environment previously as-
sociated with this drug (the open-ﬁeld apparatus, in the present study)
in a free-drug session. Instead, ethanol exerts its memory effects
through a phenomenon called state-dependency [30], which is revers-
ible by pre-test ethanol administration [34]. Thus, ethanol-induced con-
ditioning remains silent but present, and is expressed in a subsequent
ethanol challenge, which makes extinction strategies difﬁcult. Indeed,
this difﬁculty was shown by the persistent expression of ethanol-
induced behavioral sensitization in the ethanol control group of Exper-
iment 2 even after a 15-day withdrawal period with re-exposure to the
open-ﬁeld apparatus for 8 consecutive days (group Eth–Sal, Fig. 4c).
Therefore, recent efforts to develop effective treatments for addic-
tion have focused on manipulations of learning and memory processes
involved in encoding drug-cue associations. Among them, the re-
consolidation phenomenon has been extensively used [6]. However, it
requires a brief re-exposure to the test environment cues before the
pharmacological intervention, while in the strategy proposed in the
present study (counter-sensitization) animals are re-exposed to the
drug-associated context only and right after the pharmacological thera-
py intervention. Thus, re-consolidation strategies could be dangerouserlocomotion induced by ethanol (Eth, 1.8 g/kg) (Day 1) and ethanol-induced behavioral
the behavioral effects of i.p. treatment with either ayahuasca (Aya, 100 or 300 mg/kg)
subsequent saline (Day 30) and ethanol (Day 32) challenges. Data are reported asmean±
compared with Sal (a) or Sal–Sal (c) on the same experimental day;♦ p b 0.05 compared
is of variance (ANOVA) followed by Tukey's test or paired Student's t-test.
35A.J. Oliveira-Lima et al. / Physiology & Behavior 142 (2015) 28–36regarding relapse and perhaps not feasible in the clinic. The tactic pro-
posed herein would not present this risk.
In this scenario, the clinical implications of the present ﬁndings
might be far reaching. Although some programs for addiction recovery
claim improved health outcomes for patients who combine ayahuasca
during treatment [23,45], neither has been evaluatedwith sufﬁcient sci-
entiﬁc rigor to provide deﬁnitive evidence of the success of their ap-
proaches [39]. In the present study, we demonstrated that ayahuasca
not only inhibits early behaviors associatedwith initiation and develop-
ment of drug addiction, but also showed effectiveness in reversing long-
term drug effect expression, inhibiting the reinstatement of ethanol-
induced behavioral sensitization when administered in the ethanol-
associated environment without exerting addictive potential.
5. Conclusions
Ayahuasca inhibited the initiation and development of ethanol-
induced behavioral sensitization, also showing effectiveness in
preventing its reinstatement when administered in the ethanol-
associated environment without exerting addictive potential.
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